


(Rs. in crores except per share data)				
Statement of Consolidated Results for the Quarter Ended 30-Jun-2018				
Particulars	Quarter ended			Year ended
	30-Jun-2018 (Unaudited)	31-Mar-2018 (Audited) (Refer Note 6)	30-Jun-2017 (Unaudited)	31-Mar-2018 (Audited)
Revenue				
Net sales	1834	1666	1336	5825
Other operating income	38	42	26	125
Revenue from operations (net)	1872	1708	1362	5950
Other income	27	42	105	299
Total revenue	1899	1750	1467	6249
Expenses				
Cost of materials consumed	324	348	250	1039
Purchases of stock-in-trade	248	290	200	997
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(14)	(175)	(49)	(362)
Employee benefits expense	346	317	263	1135
Finance costs	122	121	56	308
Depreciation, amortisation and impairment expense	150	151	80	409
Other expenses	491	564	401	1792
Total expenses	1667	1616	1201	5318
Profit before tax	232	134	266	931
Tax expense				
Current Tax	53	54	41	199
Deferred Tax	16	(143)	37	(8)
Short / (excess) provision of earlier periods	-	(5)	-	62
Total tax expense	69	(94)	78	253
Net Profit for the period	163	228	188	678
Attributable to :				
- Owners of the company	163	228	188	678
- Non controlling Interest *	0	0	0	0
Other Comprehensive Income				
Items that will not be reclassified to profit or loss	(1)	8	(3)	(0)
Income tax relating to items that will not be reclassified to profit or loss	-	(1)	1	2
Items that will be reclassified to profit or loss	(73)	(68)	(75)	(202)
Income tax relating to items that will be reclassified to profit or loss	25	17	23	59
Total other comprehensive income	(49)	(44)	(54)	(141)
Total Comprehensive Income	114	184	134	537
Attributable to :				
- Owners of the company	114	184	134	537
- Non controlling Interest *	0	0	0	0
Paid-up equity share capital (Face value of Rs. 5 each)	84.62	84.62	84.62	84.62
Other Equity excluding Revaluation Reserves				4537
Earnings per share(of Rs. 5/- each) (not annualised for the quarter):				
Basic	9.66	13.55	11.08	40.07
Diluted	9.66	13.55	11.08	40.07

* Less than Rs. 1 crore



Notes:

- 1 The above results were reviewed by the Audit and Risk Management Committee and approved by the Board of Directors of the Parent Company, in their respective meetings held on 02-August-2018. The auditor have carried out review of the above said results. There is no qualification in the auditors report on this statement of financial results.
- 2 The consolidated financial results include the financial results of seventeen wholly owned subsidiaries and one partnership firm with that of the Company.
- 3 The Group operates in a single segment i.e Generic Formulation Business.
- 4 The Parent Company has acquired branded business of Unichem Laboratories Limited for India and Nepal on a going concern basis by way of slump sale on 14-Dec-2017. The quarter ended 30-Jun-2018 and the quarter and year ended 31-Mar-2018 includes revenue and expenses (including amortisation and interest) of the acquired business.
- 5 Torrent Pharma Inc., wholly owned subsidiary of Parent Company, has acquired 100% equity shares of Bio-Pharm Inc., on 18-Jan-2018. The quarter ended 30-Jun-2018 and the quarter and year ended 31-Mar-2018 includes revenue and expenses (including amortisation and interest) of the acquired entity.
- 6 The figures for the quarter ended 31-Mar-2018 is the balancing figures between audited figures in respect of the full financial year and for the period upto the end of the third quarter of financial year, which were subject to limited review.
- 7 (a) The listed Non Convertible Debentures of the Parent Company aggregating Rs. 1315 crores as on 30-Jun-2018 (previous year ended Rs. 1399 crores) are secured by way of first pari passu charge created through mortgage on certain specified immovable & movable assets and hypothecation of identified trademarks of the Parent Company and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
(b) The listed Non Convertible Debentures of the company aggregating Rs. 1000 crores as on 30-Jun-2018 (previous year ended Rs. 1000 crores) to be secured by way of first pari passu charge on certain specified immovable & movable assets and identified trademarks of the Company.
- 8 Effective 1 April 2018, the Company has adopted Ind AS 115 "Revenue from Contracts with Customers". The adoption of the standard did not have material impact on the financial results of the Group.
- 9 The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.

For TORRENT PHARMACEUTICALS LIMITED


SAMIR MEHTA
Executive Chairman

Place : Ahmedabad,Gujarat
Date : 02-August-2018

